Page last updated: 2024-10-15

n-(deoxyguanosin-8-yl)acetylaminofluorene

Description

N-(deoxyguanosin-8-yl)-2-acetylaminofluorene : Guanosine substituted at the purine 8-position by an acetyl(9H-fluoren-2-yl)amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135440430
CHEBI ID75810
SCHEMBL ID2687929
MeSH IDM0070677

Synonyms (15)

Synonym
8-[acetyl(9h-fluoren-2-yl)amino]-2'-deoxyguanosine
acetylaminofluorene-dg
37819-60-6
n-(deoxyguanosin-8-yl)acetylaminofluorene
n-(deoxyguanosin-8-yl)-n-acetyl-2-aminofluorene
dg-8-aaf
EPITOPE ID:192847
dg-c8-aaf
CHEBI:75810 ,
n-(deoxyguanosin-8-yl)-2-acetylaminofluorene
SCHEMBL2687929
Q27145561
n-[2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-oxo-1h-purin-8-yl]-n-(9h-fluoren-2-yl)acetamide
n-[2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-oxo-3h-purin-8-yl]-n-(9h-fluoren-2-yl)acetamide
AKOS040750093
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
guanosinesAny purine ribonucleoside that is a derivative of guanosine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (31.11)18.7374
1990's17 (37.78)18.2507
2000's10 (22.22)29.6817
2010's4 (8.89)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]